EcoDrugPlus

Hypocretin Receptor 2

Ensembl ID : ENSAPOG00000021005
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSAPOG00000007959
Gene Symbol: LOC110963435
3 Cross references
212 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSAPOG00000005113
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSAPOG00000024385
Gene Symbol: IMPDH2
4 Cross references
202 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSAPOG00000017764
Gene Symbol: LOC110948563
4 Cross references
258 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b-Like

Ensembl ID : ENSAPOG00000015613
Gene Symbol: LOC110964421
4 Cross references
258 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b-Like

Ensembl ID : ENSAPOG00000022662
Gene Symbol: LOC110964877
3 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSAPOG00000017974
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSAPOG00000023492
Gene Symbol: IGF1R
3 Cross references
206 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSAPOG00000003154
Gene Symbol: INSR
3 Cross references
201 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSAPOG00000017568
Gene Symbol: INSRA
1 Cross references
190 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSAPOG00000023001
Gene Symbol: LOC110967773
3 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).